MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions

Hypomagnesemia in Type 2 Diabetic Patients

Interventions

DRUG

Magnesium L-lactate dihydrate

Magnesium L-lactate dihydrate 10 mEq extended release caplets

DRUG

Placebo Oral Tablet

Placebo will have the same appearance, taste, odor and mode of administration as MLD10.